Merck Serono has expanded its partnership with Ablynx, entering a third agreement to discover and develop Nanobodies against two osteoarthritis targets. The companies will utilize the unique Nanobody features to develop multi-specific products with extended half-lives. Ablynx will receive an upfront payment of $27 million and will be responsible for all activities and costs for each program, excluding manufacturing costs and costs for certain in vivo models, up to the delivery of the preclinica...